Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NGM Biopharmaceuticals, Inc. - Common Stock (NQ:NGM)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NGM Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why NGM Biopharmaceuticals Dived by 41% on Monday
The results of a hepatitis drug candidate's clinical trial were not good. 
Via The Motley Fool
52 Biggest Movers From Yesterday
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,... 
Via Benzinga
Exposures Product Safety
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Analyst Reactions on NGM Biopharmaceuticals Disappointing Aldafermin Data in NASH Study
Today, NGM Biopharmaceuticals Inc (NASDAQ: NGM) reported disappointing results from the Phase 3 trial of aldafermin in NASH patients. What Happened: The... 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 250 Points; Scopus BioPharma Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.75% to 34,462.98 while the NASDAQ rose 1.64% to 13,691.64. The S&P also rose, gaining 1.25% to 4,207.76. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today
Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 101.34% to $12.0 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 17.5... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge
Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, gaining 1.04% to 4,199.05. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
35 Stocks Moving In Monday's Mid-Day Session
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 123.7% to $13.33 after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive... 
Via Benzinga
Exposures Product Safety
Mid-Morning Market Update: Markets Open Higher; Xeris Pharmaceuticals To Acquire Strongbridge Biopharma
Following the market opening Monday, the Dow traded up 0.50% to 34,378.59 while the NASDAQ rose 1.18% to 13,629.81. The S&P also rose, gaining 0.83% to 4,190.35. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
NGM Stock Crashes As NASH Drug Joins Gilead, Genfit With Notable Flops
NGM Biopharmaceuticals joined a raft of biotech companies with a failed hepatitis treatment on Monday, leading NGM stock to crash. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Strongbridge Biopharma (NASDAQ:SBBP) stock moved upwards by 14.1% to $2.75 during Monday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study
NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (... 
Via Benzinga
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies. Its stock is down just 6.2% year-to-date... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.